title: Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.
abstract: Levels of soluble CD14 (sCD14) were longitudinally measured in 85 human immunodeficiency virus (HIV)-infected subjects during long-term receipt of suppressive combined antiretroviral therapy (cART) and compared to those in young and elderly HIV-negative control subjects. cART did not normalize sCD14 levels; rather, the HIV-infected group displayed a significantly higher sCD14 level at baseline (ie, before cART initiation), 1 year after cART initiation, and 5 years after cART initiation, compared with both control groups. Furthermore, the baseline CD4(+) T-cell count was inversely associated with the baseline sCD14 level. Our results point to the necessity of complementary therapies to treat the activated/inflamed status associated with chronic HIV infection and to the benefits of early initiation of cART.
authors: Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Spain.
authors: Gema
authors: G
authors: Méndez-Lagares
authors: M Concepción
authors: MC
authors: Romero-Sánchez
authors: Ezequiel
authors: E
authors: Ruiz-Mateos
authors: Miguel
authors: M
authors: Genebat
authors: Sara
authors: S
authors: Ferrando-Martínez
authors: María Á
authors: MÁ
authors: Muñoz-Fernández
authors: Yolanda M
authors: YM
authors: Pacheco
authors: Manuel
authors: M
authors: Leal
mesh_terms: D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000472:pathogenicity; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012995:Solubility; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D003510:Cyclohexanes; D018950:Lipopolysaccharide Receptors; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc